Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Current Assets (2019 - 2021)

Greenwich LifeSciences filings provide 3 years of Current Assets readings, the most recent being $28.9 million for Q3 2021.

  • Quarterly Current Assets rose 361.98% to $28.9 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $28.9 million through Sep 2021, up 361.98% year-over-year, with the annual reading at $28.7 million for FY2020, 419217.85% up from the prior year.
  • Current Assets hit $28.9 million in Q3 2021 for Greenwich LifeSciences, down from $29.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $30.4 million in Q1 2021 and bottomed at $6835.0 in Q4 2019.
  • Average Current Assets over 3 years is $20.7 million, with a median of $28.8 million recorded in 2020.
  • The largest annual shift saw Current Assets soared 419217.85% in 2020 before it soared 361.98% in 2021.
  • Greenwich LifeSciences' Current Assets stood at $6835.0 in 2019, then soared by 419217.85% to $28.7 million in 2020, then grew by 0.86% to $28.9 million in 2021.
  • Per Business Quant, the three most recent readings for GLSI's Current Assets are $28.9 million (Q3 2021), $29.8 million (Q2 2021), and $30.4 million (Q1 2021).